Anvifen, capsules 250mg, 20pcs

Composition

Active ingredient:  

aminophenylbutyric acid hydrochloride-250 mg

Auxiliary substances:

iprolose — 2 mg;

colloidal silicon dioxide-8 mg;

lactose-86.5 mg;

magnesium stearate-3.5 mg

Solid Gelatin Capsule:

for a dosage of 250 mg — water, gelatin, azorubin dye (E 122), diamond blue dye (E 133), titanium dioxide (E 171)

Pharmacological action

Pharmacological action – antiplatelet, tranquilizing, nootropic, anticonvulsant, antioxidant.

Pharmacodynamics

A nootropic agent that facilitates GABA-mediated transmission of nerve impulses to the central nervous system (direct action on GABAergic receptors). The tranquilizing effect is combined with the activating effect. It also has antiplatelet, antioxidant and some anticonvulsant effects.

Improves the functional state of the brain by normalizing its metabolism and influencing cerebral blood flow (increases volumetric and linear velocity, reduces vascular resistance, improves microcirculation, and has an antiplatelet effect). It prolongs the latent period and shortens the duration and severity of nystagmus.

It does not affect the choline and adrenergic receptors. Reduces vasovegetative symptoms (including headache, heavy head, sleep disturbance, irritability, emotional lability). During the course, it increases physical and mental performance (attention, memory, speed and accuracy of sensory-motor reactions).

Reduces symptoms of asthenia (improves well — being, increases interest and initiative-motivation of activity) without sedation or excitement.

Helps to reduce feelings of anxiety, tension and anxiety, normalizes sleep.

In the elderly, it does not cause CNS depression, and most often there is no muscle-relaxing aftereffect.

Pharmacokinetics

Suction and distribution

Absorption is high, penetrates well into all body tissues and through the BBB (about 0.1% of the administered dose of the drug penetrates into the brain tissue, and to a much greater extent in young and elderly people). Evenly distributed in the liver and kidneys.

Metabolism and elimination

Metabolized in the liver-80-95%, metabolites are pharmacologically inactive. It doesn’t accumulate. After 3 hours, it begins to be excreted by the kidneys, while the concentration in the brain tissue does not decrease and is detected for another 6 hours. About 5% is excreted unchanged by the kidneys, partially – with bile.

Indications

Asthenic and anxiety-neurotic states. Stuttering, tics, and enuresis in children.

Insomnia and nighttime anxiety in the elderly.

Meniere’s disease, dizziness associated with vestibular analyzer dysfunctions of various origins; prevention of motion sickness in kinetoses.

As part of the complex therapy of alcohol withdrawal syndrome for the relief of psychopathological and somatovegetative disorders.

Use during pregnancy and lactation

Contraindicated during pregnancy and lactation (breastfeeding).

Contraindications

Hypersensitivity, pregnancy, breast-feeding, children under 3 years of age.

With caution:  with erosive and ulcerative lesions of the gastrointestinal tract, liver failure.

Side effects

Drowsiness, nausea. Increased irritability, agitation, anxiety, dizziness, headache (at the first reception), allergic reactions.

Interaction

Prolongs and enhances the effect of sleeping pills, narcotic analgesics, neuroleptics, antiparkinsonian and antiepileptic drugs.

How to take, course of use and dosage

Inside, after meals,2-3-week courses.

Adults and children from 14 years of age — 250-500 mg 3 times a day (the maximum daily dose is 2500 mg). Children 3-8 years – 50-100 mg 3 times a day; 8-14 years-250 mg 3 times a day.

A single maximum dose for adults and children from 14 years of age is 750 mg, for persons over 60 years of age — 500 mg, for children under 8 years of age — 150 mg, from 8 to 14 years of age — 250 mg.

Alcohol withdrawal syndrome: 250-500 mg 3 times a day and 750 mg at night, with a gradual decrease in the daily dose to the usual for adults.

Treatment of vertigo in patients with vestibular dysfunction and Meniere’s disease: 250 mg 3 times a day for 14 days.

Prevention of motion sickness: 250-500 mg once,1 hour before the expected start of pitching or when the first symptoms of seasickness appear.

The anti-motion sickness effect of Anvifen is enhanced by increasing the dose of the drug. At the onset of severe manifestations of seasickness (vomiting, etc. ), the appointment of the drug Anvifen is ineffective even in doses of 750-1000 mg.

Overdose

Symptoms:  severe drowsiness, nausea, vomiting, fatty liver disease (taking more than 7 g), eosinophilia, decreased blood pressure, impaired renal function.

Treatment:  gastric lavage, use of activated charcoal and symptomatic therapy.

Special instructions

With prolonged use, it is necessary to periodically monitor the indicators of liver and peripheral blood functions.

Influence on the ability to drive vehicles and work with mechanisms.

It is necessary to refrain from potentially dangerous activities that require increased concentration of attention.

Capsule Form of production

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

3 years

Active ingredient

Aminophenylbutyric acid

Conditions of release from pharmacies

By prescription

Dosage form

Capsules

Description

Children as prescribed by a doctor, Adults as prescribed by a doctor, Children over 3 years of age

Indications

Asthenia, Neurosis, Increased nervous Excitability, Meniere’s disease, Seasickness, Enuresis, Alcoholism, Hangover, Insomnia